ERBB2 and cancer: Trastuzumab could not only play the role of active targeting ligand for binding to the HER-2/neu receptor on target cancer cells but also prevent homodimerization or heterodimerization (Her2/Her3) of receptors, finally inhibiting the activation of MAPK and PI3K/AKT cellular signaling pathways to stop the growth of cancer cells.